The low specificity of AFP as a biomarker for surveillance for HCC may be explained by several factors, such as the transient rise in AFP levels with exacerbations of hepatitis among patients with cirrhosis or chronic liver disease, flares of underlying liver disease such as hepatitis B or C virus infections, and the development of cancer. The gene discussed is AFP; the disease is hepatitis A virus infection.